RARITAN, N.J. – Another longtime New Jersey business facility is heading for the exits.
QuidelOrtho plans to close its 66-acre Route 202 campus in Raritan Borough in 2027, according to Mike Deak’s reporting for MyCentralJersey.com.
The medical diagnostics company, headquartered in San Diego, began winding down operations after announcing the transition in 2025. A spokesperson cautioned that the closure timetable could change.
The shutdown is part of a broader consolidation effort expected to save the company approximately $20 million annually. How many employees will be affected? QuidelOrtho declined to provide a number, Deak reported.
That leaves workers and the surrounding community with a pretty significant unanswered question.
There’s also a substantial property at stake: Deak reports that the campus is assessed at $52.98 million; the annual property tax bill is approximately $1.66 million. Closing the facility doesn’t automatically erase that tax obligation, but the company hasn’t publicly outlined what comes next for the site.
The departure will close a chapter stretching back to 1945, when Johnson & Johnson’s Ortho Pharmaceutical purchased the property. J&J sold Ortho Clinical Diagnostics in 2014; its merger with Quidel followed in 2022.
The company attributes this decision to global consolidation and cost reductions. That’s the stated explanation. For Raritan, the practical questions are considerably closer to home: How many jobs disappear, what replaces the operation, and how long does the community have to wait for answers?
Meanwhile, QuidelOrtho is only the latest in a rapidly growing line of companies looking to shrink their Garden State footprint – or eliminate it altogether – in the first year of Mikie Sherrill’s gubernatorial administration.
